Tocilizumab in psoriatic arthritis due to failure of tumor necrosis factor alpha blockers
Experience in two cases
Abstract
In psoriatic arthritis, the blocking of tumor necrosis factor alpha (anti-TNF) is the most suitable option when modifying antirheumatic drugs fail. The efficacy and safety of anti-TNF are largely supported by the literature; however, in some cases, adverse events may occur or the desired efficiency is not achieved. Therapeutic alternatives in these patients are bounded; inhibition of interleukin 6 could be an option. We present two cases of patients with resistant anti-TNF receiving tocilizumab, in which we can observe significant differences in the efficacy profile of the drug.References
I. Gladman DD, Shuckett ML, Russell JC, et al. Pso-riatic Arthritis (PSA) – An analysis of 220 patients. Quarterly Journal of Medicine 1987; 62:127-41.
II. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41(6):1103-10.
III. Soriano ER, Rosa J, Velozo E, Schpilberg M, Ima-mura PM, et al. Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumato-logy 2011; 50 (4):729-34.
IV. Atzeni F, Ventura D, Batticciotto A, Boccassini L, Sarzi-Puttini P. Interleukin 6 blockade: tocilizumab in psoriatic arthritis. J Rheumatol 2012; 89:97-9.
V. Kuijk V, Tak PP. Synovitis in psoriatic arthritis: im-munohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep 2011; 13:353-9.
VI. Wendling D, Letho-Gyselinck H, Guillot X et al. Psoriasis onset with tocilizumab treatment for rheu-matoid arthritis. J Rheumatol 2012; 39:657.
VII. Soriano ER, Rosa J. Update on the treatment of peripheral arthritis in psoriatic arthritis. Curr Rheumatol Rep 2009; 11:270-7.
VIII. Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012; 79:85-7.
IX. Kagari T, Doi H, Shimozato T. The importance of IL-1 beta and TNF-alpha, and the non-involvement of IL-6, in the development of monoclonal antibo-dy-induced arthritis. J Immunol 2002; 169:1459-66.
X. Iwakura Y, Nakae S, Saijo S, et al. The roles of IL-17A in inflammatory immune responses and host defence against pathogens. Immunol Rev 2008; 226:57-79.
XI. Ogata A, Kumanogoh A, Tanaka T. Pathological role of interleukin-6 in psoriatic arthritis. Arthritis 2012; 2012:1-6.
Copyright (c) 2014 Argentine Journal of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
